New Investigator Initiated Research Data Demonstrate Efficacy and Safety of the Bridge to Life's VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System in Multiple Organ Transplants
PR Newswire
DULUTH, Ga., June 23, 2026
Studies in human uterus and small intestine transplants, including head-to-head comparison with normothermic oxygenated perfusion, presented at 2026 Annual Meeting of the American Transplant Congress (ATC) in BostonDULUTH, Ga., June 23, 2026 /PRNewswire/ -- New clinical data presented at the 2026 Annual Meeting of the American Transplant Congress (ATC) this week have demonstrated that hypothermic oxygenated perfusion (HOPE) delivered using the VitaSmart System was feasible and was associated with favorable preservation parameters in human uterus and small intestine research grafts, further supporting the potential for HOPE to benefit multiple organs in future transplantation research. The FDA-cleared labeling for VitaSmart™ currently supports hypothermic oxygenated perfusion of donor livers prior to transplantation in both Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD) donors, within defined donor criteria. The studies were presented orally, one during the Plenary Session.
